Genprex (GNPX) Non Operating Interest Expenses (2017 - 2025)
Genprex (GNPX) posted Non Operating Interest Expenses of $455549.0 for Q3 2025, up 1389.5% on a QoQ basis from $30584.0 in Q2 2018.
Powered by 
Analysis
Genprex (GNPX) Non Operating Interest Expenses (2017 - 2025) Analysis & Trends
Genprex has reported Non Operating Interest Expenses for 3 years, with the latest figure at $455549.0 in Q3 2025.
- On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $455549.0 in Q3 2025; TTM through Sep 2025 was $455549.0, a N/A change from a year earlier, with the FY2018 full-year figure at $37982.0, up 1909.63% from the prior year.
- Non Operating Interest Expenses was $455549.0 for Q3 2025 at Genprex, up from $30584.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $455549.0 in Q3 2025, with the low at $455549.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 4.00 Bn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -5.80 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 14.37 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 2.95 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 160,000.00 |
| 10 | Genprex | 1.61 Mn | -13.55 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 455,549.00 |
| Jun 30, 2018 | 30,584.00 |
| Mar 31, 2018 | 7,398.00 |
| Dec 31, 2017 | 1,890.00 |